Table 2.
Correlations between levels of NEP, ET-1, NFκB expression, and clinicopathological characteristics.
| Characteristic | NEP | P | ET-1 | P | NFκB | P | |||
|---|---|---|---|---|---|---|---|---|---|
| low | high | low | high | low | high | ||||
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | ||||
| Pre-op PSA | |||||||||
| <10 | 28 (96.6) | 34 (82.9) | 0.076 | 32 (94.1) | 30 (83.3) | 0.277 | 35 (83.3) | 27 (96.4) | 0.191 |
| ≥10 | 1 (3.4) | 7 (17.1) | 2 (5.9) | 6 (16.7) | 7 (16.7) | 1 (3.6) | |||
| Gleason score | |||||||||
| ≤7 (3 + 4) | 20 (55.6) | 30 (88.2) | 0.003 | 19 (55.9) | 31 (86.1) | 0.008 | 37 (74) | 6 (30) | 0.001 |
| ≥7 (4 + 3) | 16 (44.4) | 4 (11.8) | 15 (44.1) | 5 (13.9) | 13 (26) | 14 (70) | |||
| pT stage | |||||||||
| ≤2 | 17 (47.2) | 25 (73.5) | 0.030 | 14 (41.2) | 28 (77.8) | 0.003 | 32 (76.2) | 11 (39.3) | 0.003 |
| ≥3 | 19 (52.8) | 9 (26.5) | 20 (58.8) | 8 (22.2) | 10 (23.8) | 17 (60.7) | |||
| SMs | |||||||||
| (−) | 22 (61.1) | 27 (79.4) | 0.121 | 20 (58.8) | 29 (80.6) | 0.068 | 33 (76.7) | 16 (59.3) | 0.180 |
| (+) | 14 (38.9) | 7 (20.6) | 14 (41.2) | 7 (19.4) | 10 (23.3) | 11 (40.7) | |||
Pre-op PSA: preoperative PSA; pT stage: pathologic TNM stage; SMs: surgical margins; n: number of patients; P: statistical value.